The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 07, 2017

Filed:

May. 22, 2013
Applicant:

Instytut Biotechnologii I Antybiotyków, Warsaw, PL;

Inventors:

Piotr Borowicz, Warsaw, PL;

Andrzej Płucienniczak, Warsaw, PL;

Jerzy Mikołajczyk, Warsaw, PL;

Jarosław Antosik, Skierniewice, PL;

Jacek Pstrzoch, Rajszwe, PL;

Justyna Bernat, Magdalenka, PL;

Diana Mikiewicz-Syguła, Warsaw, PL;

Monika Bogiel, Pruszkow, PL;

Dorota Stadnik, Warsaw, PL;

Graźyna Płucienniczak, Warsaw, PL;

Boźena Tejchman-Małecka, Warsaw, PL;

Tadeusz Głąbski, Warsaw, PL;

Iwona Sokołowska, Warsaw, PL;

Dariusz Kurzynoga, Warsaw, PL;

Anna Wojtowicz-Krawiec, Warsaw, PL;

Marcin Zieliński, Warsaw, PL;

Malgorzata Kęsik-Brodacka, Warsaw, PL;

Natalia Łukasiewicz, Warsaw, PL;

Violetta Cecuda-Adamczewska, Warsaw, PL;

Monika Pawłowska, Warsaw, PL;

Tomasz Pawlukowiec, Deszczno, PL;

Jacek Stępniewski, Nowa Iwiczna, PL;

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/28 (2006.01); C07K 5/00 (2006.01); C07K 7/00 (2006.01); C07K 16/00 (2006.01); C07K 17/00 (2006.01); C07K 14/62 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/28 (2013.01); C07K 14/62 (2013.01); A61K 38/00 (2013.01);
Abstract

The invention relates to an insulin analogue or its pharmaceutically acceptable salt, pharmaceutical composition with prolonged therapeutic effect, application of the insulin analogue, dosage method and method of treatment of diabetes. In more detail, the solution pertains to compounds being stable insulin analogues which are pharmaceutically active and characterized by a prolonged, flat, truly peakless course of glucose concentration vs. time during repeated administration and which do not show strong 24 hours fluctuations of glucose concentration, or the so-called 'sawteeth effect', during this time. Results of studies of compounds included in the scope of this application indicate an improvement in the effects of diabetes treatment by avoiding the hitherto occurring adverse influence of changes in glucose concentration throughout the entire day on a patient's organism, e.g. night hypoglycaemias, because truly peakless, long-acting insulin should reproduce correct endogenous insulin secretion in the therapy, as is provided by a healthy pancreas at a proper and constant 24 hours level.


Find Patent Forward Citations

Loading…